Kotowicz Beata, Fuksiewicz Malgorzata, Jodkiewicz Magdalena, Makowka Agata, Jagiełło-Gruszfeld Agnieszka
Cancer Biomarkers and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
Department of Clinical Nutrition, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Breast Cancer (Auckl). 2025 Aug 25;19:11782234251369463. doi: 10.1177/11782234251369463. eCollection 2025.
The purpose of this study was to determine the prognostic utility of vitamin D concentrations and BMI (body mass index) values and the systemic immune-inflammation index (SII), the systemic inflammation response index (SIRI) and the pan-immune-inflammation value (PIV) to predict the achievement of a complete response to neoadjuvant treatment (NAT) in patients with breast cancer. The correlations between systemic inflammatory response indices and vitamin D concentrations and BMI values were also analysed.
The study included 96 patients with breast cancer, prior to the start of NAT, of which 51 patients were diagnosed with triple-negative breast cancer (TNBC) and 45 patients with human epidermal growth factor receptor type 2 (HER2)-positive type.
The SIRI and PIV indices were shown to be significantly higher in patients with TNBC ( = .001; = .001) than in patients with HER2. There were no statistical differences in SII, SIRI, PIV, BMI, and vitamin D, according to the response to NAT treatment (pCR vs non-pCR). In the HER2+ group without pCR after NAT, there was a positive correlation of the SII coefficient with BMI values ( = .41; = .045). Furthermore, in the entire HER2+ group (irrespective of the NAT response), SII values were negatively correlated with vitamin D levels ( = -0.39; = .008).
In patients with breast cancer, high SIRI and PIV values may indicate the biological subtype of TNBC. In the HER2+ group, higher SII values were associated with low vitamin D concentrations and elevated BMI.
本研究旨在确定维生素D浓度、体重指数（BMI）值以及全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）和全免疫炎症值（PIV）对预测乳腺癌患者新辅助治疗（NAT）达到完全缓解的预后效用。还分析了全身炎症反应指标与维生素D浓度和BMI值之间的相关性。
该研究纳入了96例在NAT开始前的乳腺癌患者，其中51例被诊断为三阴性乳腺癌（TNBC），45例为人类表皮生长因子受体2（HER2）阳性型。
TNBC患者的SIRI和PIV指数显著高于HER2患者（=0.001；=0.001）。根据NAT治疗反应（pCR与非pCR），SII、SIRI、PIV、BMI和维生素D无统计学差异（p值）。在NAT后未达到pCR的HER2+组中，SII系数与BMI值呈正相关（=0.41；=0.045）。此外，在整个HER2+组（无论NAT反应如何）中，SII值与维生素D水平呈负相关（= -0.39；=0.008）。
在乳腺癌患者中，高SIRI和PIV值可能表明TNBC的生物学亚型。在HER2+组中，较高的SII值与低维生素D浓度和升高的BMI相关。
